Orbimed Advisors Sells Shares of Enliven Theapeutics

Orbimed Advisors sold approximately $12.67 million worth of Enliven Therapeutics (NASDAQ:ELVN) shares, representing 3.67% of its indirect holdings in the company. Despite this sale, Orbimed still holds a significant stake with over 7 million shares remaining.

By Brendan Coffey, The Motley Fool Wed, June 24, 2026 at 10:32 PM GMT+3 5 min read · Yahoo Finance · June 24, 2026, 19:32 UTC

Orbimed Advisors Sells Shares of Enliven Theapeutics

Tickers: $ELVN

Topics: Enliven Therapeutics OrbiMed Advisors SEC Form 4 filing

Read the full article at Yahoo Finance

More World news

Federal Reserve to Designate October 2027 Meeting as Non-Voting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Sprott Physical Platinum and Palladium Trust Reports Q3 Net Income Decline Seeking Alpha · November 12, 2026, 17:47 UTC
Nvidia CEO Jensen Huang Resigns Amidst Market Volatility and AI Sector Shifts Motley Fool · November 12, 2026, 17:45 UTC
Honda to Transition CR-V Lineup to All-Hybrid Powertrains by 2027 Seeking Alpha · November 12, 2026, 17:43 UTC
Sprott Physical Silver Trust USD Reports Q3 Net Income of $425.83 Million Seeking Alpha · November 12, 2026, 17:44 UTC
Nvidia CEO Jensen Huang Resigns Amid Allegations of Personal Misconduct and China Export Control Concerns The Verge · November 12, 2026, 17:44 UTC
NYSE Sees $500 Billion in Market Cap Transfers from Competitors in 2026 PR Newswire · November 12, 2026, 17:45 UTC
Hyperion DeFi Reports Record Net Income and Positive Operating Cash Flow in Q3 2026 Motley Fool · November 12, 2026, 17:40 UTC
Suburban Propane Reports Fiscal 2026 Results with Increased Adjusted EBITDA and RNG Growth Motley Fool · November 12, 2026, 17:40 UTC
Altimmune Reports Third Quarter 2026 Financial Results Amid Increased R&D Spending Motley Fool · November 12, 2026, 17:40 UTC